Alligator Bioscience announces final outcome in rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Alligator Bioscience announces preliminary outcome in rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Alligator Bioscience publishes prospectus in connection with rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Bulletin from the extraordinary general meeting in Alligator Bioscience AB
Today, on 26 August 2026, an extraordinary general meeting was held in Alligator Bioscience AB. A summary of the adopted resolutions follows ...
Alligator Bioscience AB reports financial results for the period 1 January – 30 June 2026 and provides a business update
Strategic refocus: After the quarter, Alligator discontinued all further independent development of mitazalimab and refocused on preserving ...
Invitation to Alligator Bioscience’s earnings call on 26 August 2026
Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company whose principal asset is a financial interest i ...
Notice of extraordinary general meeting in Alligator Bioscience AB
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedis ...
Alligator discontinues independent development of mitazalimab for a strategic refocus on the HLX22 project, announces a rights issue of units of approximately SEK 125.6 million and raises bridge loans
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Alligator announces first patient dosed in investigator-initiated study of intratumoral mitazalimab in early-stage breast cancer
First patient dosed in an investigator-initiated trial evaluating intratumoral mitazalimab, with or without intratumoral nivolumab Study eva ...